基于PlGF的早孕期筛查与阿司匹林预防早产型子痫前期的临床与经济评估
本研究为回顾性队列研究,在三级母胎医学中心比较早孕期筛查并预防策略实施前后两个阶段。实施后对高风险孕妇给予阿司匹林160 mg/d至36周。
要点
- PlGF联合竞争风险模型筛查高风险孕妇后给予阿司匹林160 mg/d至36周,早产型子痫前期发生率显著下降。
- 含PlGF算法识别的高风险组阿司匹林保护效应显著,不含PlGF算法识别的高风险组未见显著效应。
- 该策略同时降低早产率,经济模型显示具有显著卫生系统成本节约潜力。
核心结论
- 真实世界中实施基于PlGF的早孕期筛查联合阿司匹林预防,显著降低早产型子痫前期及早产发生率。
- 经济模型预测该策略在全国范围内具有显著的卫生系统成本节约效应。
研究设计与样本
- 回顾性队列研究,在一家三级母胎医学中心开展,比较策略实施前阶段(2011年8月至2014年6月)与实施后阶段(2017年7月至2024年2月)。
- 风险评估采用胎儿医学基金会竞争风险算法,分别评估含PlGF与不含PlGF两种算法。
- 实施后阶段对筛查为早产型子痫前期高风险的孕妇给予阿司匹林160 mg/d至36周。
主要发现
- 早产型子痫前期发生率从1.1%降至0.6%,调整比值比为0.41(95%CI,0.25-0.68)。
- 子痫前期总发生率从2.5%降至1.4%,调整比值比为0.51(95%CI,0.37-0.70)。
- 早产率从5.9%降至4.7%,调整比值比为0.76(95%CI,0.63-0.92)。
- 含PlGF算法识别的高风险组中阿司匹林保护效应显著,调整比值比为0.51(95%CI,0.28-0.92)。
- 不含PlGF算法识别的高风险组中未观察到显著效应。
关键数值与推荐
- 阿司匹林预防方案为160 mg每日一次,持续至孕36周。
- 早产型子痫前期定义为孕37周前发生的子痫前期。
- 经济模型纳入早产新生儿管理的直接医疗费用及脑瘫的终身费用。
临床怎么用
- 对于早孕期筛查为早产型子痫前期高风险的孕妇,可考虑给予阿司匹林160 mg/d至36周。
- 筛查算法中纳入PlGF有助于更精准识别能从阿司匹林预防中获益的高风险孕妇。
局限性
- 本研究为回顾性队列设计,实施前后阶段存在时间差异。
- 经济模型基于全国出生数据推算,实际成本节约有待前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical effectiveness and economic impact of implementing first-trimester screening involving placental growth factor (PlGF) followed by aspirin prophylaxis for the prevention of preterm pre-eclampsia in routine obstetric practice. METHODS: This retrospective cohort study was conducted at a tertiary maternal-fetal medicine center that implemented a first-trimester screen-and-prevent strategy for preterm pre-eclampsia. Two time periods were compared: a preimplementation phase (August 2011 to June 2014), during which risk assessment for pre-eclampsia was performed for research purposes without prophylactic aspirin administration; and a postimplementation phase (July 2017 to February 2024), during which women who screened as high risk for preterm pre-eclampsia were given aspirin prophylaxis (160 mg daily until 36 weeks' gestation). Risk assessment was based on the Fetal Medicine Foundation competing-risks algorithm, applied with and without the inclusion of PlGF. The primary outcome was the incidence of preterm pre-eclampsia (< 37 weeks). Secondary outcomes included preterm birth (< 37 weeks), overall pre-eclampsia and estimated healthcare cost savings based on national birth data. This model included the direct medical costs of neonatal management of preterm birth and lifetime costs of cerebral palsy. Adjusted odds ratios (aORs) for preterm pre-eclampsia were estimated using multivariable logistic regression analysis. RESULTS: Among 11 061 singleton pregnancies screened between 11 + 0 and 13 + 6 weeks' gestation, 3216 were screened during the preimplementation period and 7845 during the postimplementation period. The incidence of preterm pre-eclampsia declined from 1.1% to 0.6% between phases (aOR, 0.41 (95% CI, 0.25-0.68)). The overall rate of pre-eclampsia also decreased between phases (2.5% vs 1.4%; aOR, 0.51 (95% CI, 0.37-0.70)), as did that of preterm birth (5.9% vs 4.7%; aOR, 0.76 (95% CI, 0.63-0.92)). The protective effect of aspirin was most pronounced among women identified as high risk using a PlGF-based screening algorithm (aOR, 0.51 (95% CI, 0.28-0.92)), while no significant effect was observed in the group identified as high risk using an algorithm without PlGF. An economic model projected that this strategy would prevent 403 cases of preterm pre-eclampsia annually in a national cohort of 110 000 pregnancies, with estimated cost savings of €27.7 million. CONCLUSIONS: Real-world implementation of PlGF-based screening with aspirin prophylaxis significantly reduced the incidence of preterm pre-eclampsia and preterm birth, and was associated theoretically with substantial health-system cost savings. These findings support consideration of the nationwide adoption of early screen-and-prevent strategies for hypertensive disorders of pregnancy. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Badr, Carlin, Kang, et al. Implementation of PlGF-based first-trimester screening and aspirin prophylaxis for preterm pre-eclampsia: clinical and economic evaluation. Ultrasound Obstet Gynecol. 2026. PMID: 41664568. doi:10.1002/uog.70176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。